CellFE

Today, we’re excited to announce several strategic placements of our non-viral, non-electroporative Infinity MTx platform with major pharmaceutical and biotech companies, as well as leading translational medicine centers in the cell therapy market. These partnerships represent an important milestone in our journey toward streamlining clinical manufacturing—reducing costs, accelerating workflows, and improving therapeutic potency.   💬 “We are committed to supporting our partners on their path to success and closely collaborating to overcome the scale-up and scale-out challenges that limit global accessibility to advanced cell therapies for patients,” said Alla Zamarayeva, PhD, CEO at CellFE.   With the launch of our high volume clinical-scale instrument on the horizon for 2025, we’re thrilled to continue supporting our partners as they advance their therapies toward clinical trials and regulatory approvals in the New Year.   🔗 Read the press release: https://lnkd.in/eVsN8WMU 🔗 Contact our team: https://lnkd.in/eS7gGbwT  #CellTherapy #CGT #Biotech #Pharma #Innovation #RegenerativeMedicine #Nonviral #Nonelectroporative

🌟 Gratitude Series: Celebrating Innovation in Cell Therapy Manufacturing 🌟 This week, we’re spotlighting how emerging technologies are tackling the high costs of manufacturing advanced cell therapies, making these life-saving treatments more accessible to patients worldwide. 💬 "Innovative technologies are transforming how we think about manufacturing," said Krishna C V., Senior Field Application Scientist at CellFE. "By reducing production costs and increasing scalability, these tools are opening doors for patients who might otherwise not have access to these therapies. This is how we ensure cell therapies become a global solution—not a privilege." 💡 The Current Challenge Deloitte’s 2024 Advanced Therapy Industry Report highlights “improved manufacturing technology” as a top force influencing the commercialization of therapies in the next 12-18 months, underscoring how the current cost and speed of cell therapy production remains a critical hurdle for therapeutic manufacturers. Innovators around the world are stepping up. In India, Dr. Alka Dwivedi and colleagues achieved dramatic progress by producing CAR T-cell treatments at a fraction of the typical cost, utilizing streamlined processes and novel cellular engineering technologies. Rapid, easily scalable gene editing tools - like CellFE’s Infinity MTx platform - are similarly poised to address challenges in cell therapy manufacturing by: 👉 Reducing payload requirements to material costs by up to 30%. 👉 Boosting therapeutic potency to enable fewer cells per treatment. 👉 Optimizing workflows to reduce steps and improve efficiency. From CAR T-cell breakthroughs in India to enabling technologies like the Infinity MTx, every step brings us closer to a world where life-saving cell therapies accessible for all who need them. What innovation or breakthrough are you grateful for this year? Let us know in the comments! 🔗 Deloitte 2024 Industry Report: https://lnkd.in/eDFPAutA 🔗 India’s First CAR-T Therapy: https://lnkd.in/ej8UUs5D #GratitudeSeries #CellTherapyInnovation #CGT #Nonviral #Nonelectroporative #COGS #ManufacturingEfficiency #AdvancedTherapies #LifeSciences  

📣 Don’t miss out! Alla Zamarayeva, PhD, CEO of CellFE, will be speaking at the Virtual Salon: Trendwatching for Early-Stage TechBio Companies, co-hosted by Demy-Colton and EBD Group!   As part of the TechBio series, this event brings together key thought leaders and innovators to discuss the latest trends defining the future of early-stage biotech. Alla will share her unique insights from the cell therapy industry, sharing strategies for early-stage companies to thrive in the dynamic TechBio space.   🗓 Wednesday, December 4th, 2024 ⏰ 11:00 AM - 12:15 PM EST 🔗 Register here: https://lnkd.in/gn-A6KqK   Thank you to Demy-Colton and EBD Group for hosting the event and showcasing the progress in the industry. Don’t miss this chance to gain fresh perspectives from industry leaders!   #TechBio #Innovation #CGT #CellTherapy #LifeSciences #RegenerativeMedicine #BiotechShowcase #NonViral

We're thrilled to have CellFE's CEO Alla Zamarayeva, PhD join upcoming TechBio Investor and Technology Trends panel this year! Join the Virtual Salon on Wednesday, Dec 4th at 11AM EST as panelists discuss cutting-edge technology that is shaping the future of cell and gene therapy to improve healthcare outcomes. Register to reserve your spot: 🔗 https://lnkd.in/ew5Sq_gP Schedule a meeting at Biotech Showcase 2025: 📅 https://lnkd.in/eynMeaR Demy-Colton EBD Group #BiotechShowcase #Innovation #CellTherapy #NonViral #TechBio #CGT

🧬 CAR T Therapies: Changing Lives, Restoring Hope 🧬 This week in CellFE's gratitude series, we’re reflecting on how CAR T-cell therapies are revolutionizing cancer care. For patients like Laurie Adami, who endured 12 years of chemotherapy and failed treatments for non-Hodgkin lymphoma, CAR T therapy was life changing. Just one month after receiving Kite Pharma’s CAR T therapy, Laurie was declared cancer-free—and five years later, she’s still thriving. 💬 "CAR T-cell therapies are transforming cancer treatment," shared Paul Carman, Head of Commercial, CellFE. "They provide patients not just a chance at survival but a faster, more effective alternative to exhausting treatments like chemotherapy.” 🔍 𝗛𝗼𝘄 𝗱𝗼 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝘁𝗼𝗼𝗹𝘀 𝗳𝗶𝘁 𝗶𝗻? A recent article from Stanford Cancer Institute’s Feldman Lab highlights non-viral methods as powerful alternatives to viral vectors in CAR T engineering. Combined with rapid processing tools like CellFE’s transfection system, these non-viral methods can be utilized at larger scale to deliver cell therapies faster, safer, and at lower costs. This means more patients could gain access to life-saving CAR T treatments - helping to close the gap between innovation and accessibility. Stories like Laurie’s inspire us to keep driving progress in cell therapy. 🌟 ➡️ What has inspired your team this year? 𝗦𝗵𝗮𝗿𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀! 🔗 Laurie’s full story: https://lnkd.in/eRZeduia 🔗 Feldman Lab article: https://lnkd.in/e9JS8r63 #GratitudeMonth #CellTherapy #CART #CGT #Innovation #NonViral #PatientStories #RegenerativeMedicine #Nonelectroporative #Biotech

🍂 Kicking Off a Month of Gratitude in Cell Therapy! 🍂  It’s the season to give thanks, and CellFE is cell-ebrating each week by spotlighting some of the incredible strides in cell therapy that our team is grateful for.     📣 This week: We’re starting off with a historic milestone — the FDA’s first approval of an engineered cell therapy for solid tumors!     Why is this so significant? Traditionally, CAR T-cell therapies have transformed outcomes for blood cancers, but solid tumors have been much harder to treat due to complex barriers. The recent FDA approval of Adaptimmune’s Tecelra for use on solid tumor sarcoma shows that engineered cell therapies can effectively target solid tumors, expanding the possibilities for patients with difficult-to-treat cancers and expanding a new frontier for the cell therapy industry.    💬 “This approval is a tremendous moment,” CellFE CSO, Todd Sulchek, shared. “It demonstrates the progress the scientists in the field have made in cell engineering and sets a powerful precedent for expanding cell therapy applications.”    For patients, this means new hope, especially for those facing aggressive cancers where options have been limited. For the industry, this breakthrough encourages more investment, expansion, and development into solid tumor treatments. We’re thrilled to see the progress as cell therapies move beyond blood cancers to tackle a wider range of indications, potentially impacting millions of patients’ lives.    Stay tuned each week over the next month as we continue to spotlight cell therapy breakthroughs worth cell-ebrating!    Read the press release on FDA-approval: https://lnkd.in/e_mSHWBf #celltherapy #biotech #CGT #regenerativemedicine #solidtumors #innovation #breakthroughmedicine

🌟 Meet Our Team at Terrapinn's Advanced Therapies 2024 in Philadelphia! 🌟 This week, our team is attending Advanced Therapies 2024, where the mission is clear: accelerate the advancement of cell and gene therapies to bring life-changing solutions to patients worldwide. Alla Zamarayeva, PhD, Paul Carman, and Todd Sulchek will be attending this week, so don’t miss out on the chance to learn about our innovations in non-viral delivery and workflow solutions! Attending the meeting? ➡ Schedule here: https://lnkd.in/e8Ti_YcT Not attending? ➡ Book a meeting online: https://lnkd.in/eUBZ2JRa #AdvancedTherapies2024 #NonViral #CellTherapy #GeneTherapy #Biotech #Innovation

🔊 Exciting News from CellFE! 🏙 Our CEO, Alla Zamarayeva, PhD, will be attending Demy-Colton #BioFuture2024 in #NYC this week, Oct 28-30! This is a unique opportunity to connect with us and discover how non-viral CGT tools and automation are transforming the development and manufacturing of cell therapies in healthcare. Here’s how you can connect with us: 🗓 October 28-30 📍 New York City, NY ➡️ Book a meeting with our CEO: https://lnkd.in/d-2BHMQH 📢 Don’t miss our CEO’s presentation on Wednesday, October 30th @ 10:45 AM in Track 12-B (12th Floor)! Dr. Zamarayeva will be sharing how non-viral, automation-equipped technologies are positioned to unlock manufacturing bottlenecks and deliver the next-generation of highly scalable, cost-efficient, and safer cell therapies. We’re excited to connect at BioFuture and shape the future of healthcare innovation together! #BioFuture2024 #BiotechInnovation #NonViral #NonElectroporative #CellTherapy #GeneEditing #CGT #HealthcareInnovation

✨ Meeting on the Mesa 2024 has wrapped up, and we are thrilled with all the exciting discussions that took place! ✨ Here are a few key takeaways from the conference that highlight the future of cell therapy manufacturing: 🔑 Scalability is critical – As demand for advanced therapies grows, scalable, non-viral solutions are essential to meet clinical and commercial needs. 🔑 Cost-effective manufacturing – Reducing production costs while maintaining the high quality of cell therapies is critical to improving accessibility for patients. 🔑 Shorter production times – Speeding up the manufacturing process is key to delivering therapies faster, helping to meet urgent treatment needs. If you couldn’t make it to the event, it’s not too late to connect! Reach out to our team at CellFE to learn how our non-viral workflow solutions can help optimize your cell therapy manufacturing for enhanced scalability, cost-efficiency, and faster production times. Connect with our team: https://lnkd.in/eS7gGbwT #MeetingOnTheMesa #CellTherapy #GeneEditing #NonViral #NonElectroporative #Innovation #Biotech #CellManufacturing #Scalability #LetsConnect

📣 Only TWO days left at Meeting on the Mesa, and we're already hearing so many big ideas and groundbreaking innovations! 📣 Are you ready to take the next steps in optimizing your non-viral gene editing workflow? There's still time to meet with our team at #CGMesa24 and learn how non-viral editing solutions can deliver major benefits to your cell therapy manufacturing processes. Let’s discuss how you can achieve better scalability, cell health, and reduced costs in your cell therapy manufacturing workflows via CellFE's non-viral, non-electroporative method. 📍Alla Zamarayeva, PhD and Paul Carman are attending in Phoenix this week. Don’t miss the chance to connect with them via the partnering platform or reach out to them directly. Connect at Mesa  ➡️ https://lnkd.in/edKBRYf Not Attending  ➡️ https://lnkd.in/eUBZ2JRa #MeetingOnTheMesa #CellTherapy #NonViral #NonElectroporative #Biotech #Innovation #GeneEditing #CellManufacturing